N-Acetylcysteine (NAC) is a derivative of the amino acid L-cysteine that serves as a precursor to glutathione, the body's primary antioxidant. It works by replenishing glutathione levels, supporting liver detoxification, reducing oxidative stress, and modulating glutamate neurotransmission. NAC is FDA-approved as a medication for acetaminophen overdose and is commonly used as a supplement for respiratory health, mental health conditions, and overall antioxidant support.

Overview

N-Acetyl Selank is a modified form of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences based on the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro tripeptide extension derived from the glyproline regulatory motif. The N-acetyl modification adds an acetyl group to the N-terminal threonine residue, which protects the peptide from aminopeptidase-mediated degradation and enhances lipophilicity, potentially improving intranasal bioavailability and central nervous system penetration. This structural optimization aims to extend the already favorable pharmacological profile of native Selank, which is approved in Russia as an anxiolytic and nootropic pharmaceutical.

The pharmacological profile of N-Acetyl Selank encompasses three primary domains: anxiolytic, nootropic, and immunomodulatory activity. The anxiolytic effects are mediated through allosteric modulation of GABA-A receptors (enhancing the binding of GABA and benzodiazepines without direct agonism), increased brain-derived neurotrophic factor (BDNF) expression in the hippocampus and prefrontal cortex, and modulation of serotonergic neurotransmission through effects on 5-HT metabolism and receptor sensitivity. Unlike benzodiazepines, Selank and its N-acetyl derivative produce anxiolysis without sedation, cognitive impairment, tolerance development, or physical dependence — a critical therapeutic advantage. The nootropic effects include enhanced memory consolidation, improved attention, and facilitated learning, attributed to BDNF-mediated neuroplasticity, cholinergic modulation, and stabilization of enkephalin metabolism in the brain.

The immunomodulatory dimension of N-Acetyl Selank, inherited from its tuftsin core, involves stimulation of IL-6 expression, modulation of T-helper cell balance (Th1/Th2), and enhancement of monocyte/macrophage activity. This positions N-Acetyl Selank as a uniquely multi-target compound that bridges the neuroimmune axis — addressing both the psychological and immunological components of stress-related disorders. Administration is typically intranasal at doses of 250–500 mcg per nostril, 1–3 times daily, though subcutaneous injection is also used. N-Acetyl Selank is frequently combined with N-Acetyl Semax in comprehensive nootropic protocols, as the two peptides have complementary mechanisms — Selank's anxiolytic/GABAergic profile balancing Semax's stimulatory/dopaminergic/BDNF-enhancing activity. Side effects are rare and typically limited to mild nasal irritation with intranasal use.

Mechanism of Action

Structural Basis

N-Acetyl Selank is the N-terminally acetylated form of Selank. Selank itself is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) consisting of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg, a fragment of IgG heavy chain) with a C-terminal Pro-Gly-Pro stabilizing extension developed at the Institute of Molecular Genetics, Russian Academy of Sciences. The N-acetyl group protects against aminopeptidase cleavage, extending the in vivo half-life and potentially improving CNS bioavailability.

GABAergic Anxiolysis

Selank and its N-Acetyl derivative enhance GABAergic neurotransmission in the amygdala, hippocampus, and prefrontal cortex. The peptide increases the binding affinity of GABA at GABA-A receptors through an allosteric mechanism distinct from benzodiazepines, enhancing chloride conductance and neuronal inhibition in anxiety-related circuits without producing sedation, tolerance, or physical dependence. Gene expression studies show upregulation of GABA-A receptor subunit genes in the hippocampus following Selank administration.

BDNF & Cognitive Enhancement

N-Acetyl Selank increases expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in hippocampal neurons. BDNF/TrkB signaling activates Ras/MAPK/ERK, PI3K/Akt, and PLCγ cascades that support long-term potentiation (LTP), dendritic spine formation, and neurogenesis — the cellular substrates of learning and memory. Animal studies demonstrate improved performance in passive avoidance, Morris water maze, and novel object recognition tests.

Serotonergic Modulation

Selank modulates serotonin metabolism by influencing the expression of genes encoding tryptophan hydroxylase 2 (TPH2), 5-HT transporter (SERT/SLC6A4), and MAO-A. It also modulates 5-HT1A receptor sensitivity in the dorsal raphe and hippocampus. This serotonergic modulation contributes to anxiolytic and antidepressant-like behavioral effects observed in rodent models.

Immunomodulatory Activity

The tuftsin core activates Neuropeptide Receptor 1 (NRP1) and tuftsin receptor on monocytes, macrophages, and NK cells, stimulating phagocytic activity, antigen presentation, and cytokine production. Selank normalizes the Th1/Th2 cytokine balance, increasing IL-10 and modulating IL-6 and TNF-alpha levels. This immunomodulatory profile supports its clinical use (approved in Russia) for stress-related immune suppression and recurrent infections.

Reconstitution Calculator

Research

Safety Profile

Side effects are generally mild, including potential nasal irritation, headaches, fatigue, and occasional anxiety or insomnia. It is contraindicated during pregnancy, lactation, and for those with active cancer or hypersensitivity. Long-term safety is unknown, and it is not FDA-approved for medical use.

Pharmacokinetic Profile